GlassScriptPhysician profile
Jamie Lummus
NPI 1417401415
$3,703.83
in general payments reported to CMS, 2019-2025
37 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $180 · 2022: $77.27 · 2023: $224 · 2024: $1,329 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,371 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,371.38 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $542.27 | 2022-2025 | Lynparza, Imfinzi, Calquence |
| Genzyme Corporation | $450.61 | 2023-2025 | |
| Glaxosmithkline, LLC. | $325.08 | 2024-2025 | Ojjaara, Blenrep |
| E.R. Squibb & Sons, L.L.C. | $251.95 | 2021-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $216.37 | 2024-2025 | Talvey, Rybrevant, Carvykti |
| Abbvie INC. | $216.35 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $215.05 | 2021-2025 | Iclusig, Ninlaro |
| Pfizer INC. | $170.16 | 2025 | |
| Novartis Pharmaceuticals Corporation | $153.87 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $150.60 | 2024-2025 | Lynozyfic, Libtayo |
| Puma Biotechnology, INC. | $94.19 | 2021-2024 | |
| Genentech USA, INC. | $93.40 | 2025 | Tecentriq, Polivy, Venclexta |
| Celgene Corporation | $91.39 | 2023-2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $78.80 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Beigene USA, INC. | $72.76 | 2024-2025 | Brukinsa |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $62.38 | 2024-2025 | Vyloy, Cresemba |
| Secura Bio, INC. | $56.79 | 2025 | Copiktra |
| Incyte Corporation | $47.66 | 2024-2025 | Jakafi, Zynyz, Monjuvi |
| Sobi, INC | $31.16 | 2025 | |
| Coherus Oncology, INC. | $26.82 | 2025 | |
| Exelixis INC. | $26.32 | 2025 | Cabometyx |
| Adaptive Biotechnologies Corporation | $26.30 | 2025 | Clonoseq |
| Pharmacyclics LLC, An Abbvie Company | $25.77 | 2023 | Imbruvica, Epkinly |
| Beone Medicines USA, INC. | $25.34 | 2025 | Brukinsa |
| Dendreon Pharmaceuticals LLC | $24.72 | 2024 | Provenge |
| Tersera Therapeutics LLC | $24.10 | 2025 | Xermelo |
| Rigel Pharmaceuticals, INC. | $22.59 | 2024 | Rezlidhia, Tavalisse |
| Array Biopharma INC | $22.39 | 2025 | Lorbrena, Xalkori, Mektovi |
| Bayer Healthcare Pharmaceuticals INC. | $21.26 | 2025 | |
| Agios Pharmaceuticals, INC. | $19.36 | 2025 | Pyrukynd |
| Adc Therapeutics America, INC. | $19.10 | 2024 | |
| Eisai INC. | $17.45 | 2025 | |
| Daiichi Sankyo INC. | $17.21 | 2024 | Enhertu |
| Mirati Therapeutics, INC. | $16.65 | 2024 | Krazati |
| Blueprint Medicines Corporation | $16.60 | 2025 | Ayvakit |
| Geron Corporation | $15.68 | 2025 | Rytelo |
| Seagen INC. | $15.33 | 2023 | Adcetris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Lummus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.